MedTrace Logo

VIrtual Reality in Cognitive Rehabilitation of Processing Speed for Persons With ABI

NCT05443542 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-11-08

No results posted yet for this study

Summary

One hundred participants with acquired brain injury (ABI) will be included in a randomized controlled trial, with one group playing a commercially available VR game and the control group doing activities in their everyday as cognitive training. The trial aims to investigate how VR can affect processing speed in the ABI population, and if these effects can transfer into everyday activities. The training will be performed in the participants homes, with assistance provided by the project group via phone or video conference. The training period will last five weeks. Participant's cognitive functions will be measured with questionnaires and neuropsychological tests at the start of the training period, at the end of training and sixteen weeks after the start of the intervention. In depth experiences with VR as a training method will be gathered through performing focus group interviews with some of the participants from the VR group, in addition to self-reported questionnaires from all the participants.

Conditions

Interventions

DEVICE

Virtual Reality

Game to be played is a commercially available VR game

OTHER

Control intervention

Sodoku, crossword puzzles

Sponsors & Collaborators

  • Oslo Metropolitan University

    collaborator OTHER

  • Norwegian University of Science and Technology

    collaborator OTHER

  • Sunnaas Rehabilitation Hospital

    lead OTHER

Principal Investigators

  • Marianne Løvstad, PhD · Sunnaas Rehabilitation hopsital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05443542 on ClinicalTrials.gov